Regression analysis of the relationship between intervention and anxiety, depression, sleep quality, quality of life, and clinical pregnancy rate. by Nan Tang (642590)

Subjects:

Group control-before intervention. by Nan Tang (642590)

Subjects:

Patient satisfaction with SFA intervention(%). by Nan Tang (642590)

Subjects:

Pre-Experiment. by Nan Tang (642590)

Subjects:

Between-group comparison of clinical pregnancy rate after intervention(%). by Nan Tang (642590)

Subjects:

Group SFA-after intervention. by Nan Tang (642590)

Subjects:

Intervention process of two groups. by Nan Tang (642590)

Subjects:

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

General procedure for the synthesis of B. by Xueqin lu (22250795)

Subjects:

The trends of gene expression in the metabolism of triglycerides in liver tissue. by Xueqin lu (22250795)

Subjects:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects:

¹H NMR spectra for kylo-0603. by Xueqin lu (22250795)

Subjects:

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

Subjects:

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Subjects:

The trends in the expression of inflammation-related genes in liver tissue. by Xueqin lu (22250795)

Subjects:

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. by Xueqin lu (22250795)

Subjects:

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Subjects:

The trends in the expression of fibrosis-related genes in liver tissue. by Xueqin lu (22250795)

Subjects: